Myelodysplastic syndrome natural history, complications and prognosis: Difference between revisions
Nawal Muazam (talk | contribs) No edit summary |
Nawal Muazam (talk | contribs) No edit summary |
||
| Line 14: | Line 14: | ||
:*Iron overload | :*Iron overload | ||
==Prognosis== | ==Prognosis== | ||
A variety of pathologic and risk classification systems have been developed to predict the overall survival of patients with myelodysplastic syndrome and the evolution from myelodysplastic syndrome to acute myeloid leukemia. Major prognostic classification systems include the International Prognostic Scoring System (IPSS), revised as the IPSS-R; the WHO Prognostic Scoring System (WPSS); and the MD Anderson Cancer Center Prognostic Scoring Systems. Clinical variables in these systems have included bone marrow and blood myeloblast percentage, specific cytopenias, transfusion requirements, age, performance status, and bone marrow cytogenetic abnormalities. | |||
===IPSS=== | |||
The IPSS incorporates bone marrow blast percentage, number of peripheral blood cytopenias, and cytogenetic risk group. | |||
===IPSS-R=== | |||
Compared with the IPSS, the IPSS-R updates and gives greater weight to cytogenetic abnormalities and severity of cytopenias, while reassigning the weighting for blast percentages. | |||
===WPSS=== | |||
In contrast to the IPSS and IPSS-R, which should be applied only at the time of diagnosis, the WPSS is dynamic, meaning that patients can be reassigned categories as their disease progresses. | |||
==References== | ==References== | ||
{{reflist| | {{reflist|2}} | ||
Revision as of 17:54, 11 December 2015
|
Myelodysplastic syndrome Microchapters |
|
Differentiating Myelodysplastic syndrome from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Myelodysplastic syndrome natural history, complications and prognosis On the Web |
|
American Roentgen Ray Society Images of Myelodysplastic syndrome natural history, complications and prognosis |
|
FDA on Myelodysplastic syndrome natural history, complications and prognosis |
|
CDC on Myelodysplastic syndrome natural history, complications and prognosis |
|
Myelodysplastic syndrome natural history, complications and prognosis in the news |
|
Blogs on Myelodysplastic syndrome natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Nawal Muazam M.D.[2]
Overview
Common complications of myelodysplasia include progression to acute myeloid leukemia, bone marrow failure, infection, hemorrhage, and iron overload.[1]
Natural history
If left untreated, patients with myelodysplastic syndrome may progress to develop weight loss, bone marrow failure, infection, hemorrhage, iron overload.[1]
Complications
Common complications of myelodysplasia include:[1]
- Progression to acute myeloid leukemia
- Bone marrow failure
- Infection
- Hemorrhage
- Iron overload
Prognosis
A variety of pathologic and risk classification systems have been developed to predict the overall survival of patients with myelodysplastic syndrome and the evolution from myelodysplastic syndrome to acute myeloid leukemia. Major prognostic classification systems include the International Prognostic Scoring System (IPSS), revised as the IPSS-R; the WHO Prognostic Scoring System (WPSS); and the MD Anderson Cancer Center Prognostic Scoring Systems. Clinical variables in these systems have included bone marrow and blood myeloblast percentage, specific cytopenias, transfusion requirements, age, performance status, and bone marrow cytogenetic abnormalities.
IPSS
The IPSS incorporates bone marrow blast percentage, number of peripheral blood cytopenias, and cytogenetic risk group.
IPSS-R
Compared with the IPSS, the IPSS-R updates and gives greater weight to cytogenetic abnormalities and severity of cytopenias, while reassigning the weighting for blast percentages.
WPSS
In contrast to the IPSS and IPSS-R, which should be applied only at the time of diagnosis, the WPSS is dynamic, meaning that patients can be reassigned categories as their disease progresses.